Cabozantinib and prostate cancer: inhibiting seed and disrupting soil?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 24284057.
- Also identified by DOI 10.1158/1078-0432.CCR-13-2636 and PMC identifier 3966545.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Treatment with cabozantinib, an inhibitor of MET and VEGFR2 signaling, has demonstrated clinical benefit in early trials in men with metastatic prostate cancer. Preclinical evidence suggests that cabozantinib can kill cancer cell seeds while disrupting angiogenesis and stromal cells in the metastatic soil.
Medical subject headings
- Anilides
- Antineoplastic Agents
- Bone Neoplasms
- Cell Proliferation
- Osteoblasts
- Prostatic Neoplasms
- Pyridines